Cas no 115966-23-9 (Urodilatin)

Urodilatin is a natriuretic peptide hormone primarily produced in the kidney, playing a critical role in regulating sodium excretion, blood pressure, and fluid homeostasis. Structurally similar to atrial natriuretic peptide (ANP), it exhibits potent diuretic, natriuretic, and vasodilatory effects by binding to guanylyl cyclase-coupled receptors. Its renal-specific synthesis and action make it a key target for research in cardiovascular and renal pathophysiology. Urodilatin's resistance to enzymatic degradation by neutral endopeptidase (NEP) enhances its biological stability, distinguishing it from other natriuretic peptides. Clinical investigations highlight its potential therapeutic applications in acute decompensated heart failure and renal dysfunction, owing to its targeted physiological effects.
Urodilatin structure
Urodilatin structure
Product Name:Urodilatin
CAS No:115966-23-9
MF:C145H234N52O44S3
MW:3505.92648458481
CID:191082
PubChem ID:16132416
Update Time:2025-11-02

Urodilatin Chemical and Physical Properties

Names and Identifiers

    • Urodilatin
    • Thr-Ala-Pro-Arg-Atrial Natriuretic Factor (1-28) (human, bovine, porcine)
    • THR-ALA-PRO-ARG-ATRIAL NATRIURETIC FACTOR (1-28) (
    • Thr-Ala-Pro-Arg-Atrial Natriuretic Factor (1-28) (human, bovine, porcine), Urodilatin, Ularitide
    • URODILATIN HUMAN
    • ANP,95-126
    • ANP-95-126
    • CCC
    • CDD
    • THR-ALA-PRO-ARG-ANP,HUMAN
    • THR-ALA-PRO-ARG-ATRIAL NATRIURETIC PEPTIDE
    • THR-ALA-PRO-ARG-ATRIAL NATRIURETIC PEPTIDE HUMAN
    • THR-ALA-PRO-ARG-SER-LEU-ARG-ARG-SER-SER-CYS-PHE-GLY-GLY-ARG-MET-ASP-ARG-ILE-GLY-ALA-GLN-SER-GLY-LEU-GLY-CYS-ASN-SER-PHE-ARG-TYR(DISULFIDE BRIDGE CYS11-CYS 27)
    • URODILATIN (95-126)
    • URODILATIN CCC
    • Urodilatin,Ularitide
    • THR-ALA-PRO-ARG-SER-LEU-ARG-ARG-SER-SER-CYS-PHE-GLY-GLY-ARG-MET-ASP-ARG-ILE-GLY-ALA-GLN-SER-GLY-LEU-GLY-CYS-ASN-SER-PHE-ARG-TYR
    • CCC/ANP-95-126
    • CDD/ANP-95-126
    • Urodilatin, Ularitide
    • URODILATIN CCC/ANP, 95-126
    • THR-ALA-PRO-ARG-ANP, HUMAN
    • AT42474
    • URODILATIN [MI]
    • URODILATIN ULARITIDE [MI]
    • Ularitide [INN]
    • AKOS030213250
    • DTXCID7073729
    • Anf (95-126)
    • Urodilatin ularitide
    • L-Threonyl-L-alanyl-L-prolyl-L-arginyl-L-seryl-L-leucyl-L-arginyl-L-arginyl-L-seryl-L-seryl-L-cysteinyl-L-phenylalanylglycylglycyl-L-arginyl-L-methionyl-L-aspartyl-L-arginyl-L-isoleucylglycyl-L-alanyl-L-glutaminyl-L-serylglycyl-L-leucylglycyl-L-cysteinyl-L-asparaginyl-L-seryl-L-phenylalanyl-L-arginyl-L-tyrosine cyclic (11->27)-disulfide
    • ESP-305
    • ANP 95-126
    • CHEMBL2103920
    • Human urodilatin
    • DA-58548
    • ularitidum
    • Anp (95-126)
    • UNII-740Y5J48Z8
    • ularitida
    • DB05034
    • Atriopeptin (95-126)
    • Thr-Ala-Pro-Arg-Atrial Natriuretic Factor (1-28) (human, bovine, porcine) trifluoroacetate salt
    • Atrial natriuretic peptide (95-126)
    • Urodilatin human, >=97% (HPLC)
    • DA-78761
    • 740Y5J48Z8
    • ULARITIDE [WHO-DD]
    • 115966-23-9
    • 118812-69-4
    • Ularitide
    • L-Threonyl-L-alanyl-L-prolyl-L-arginyl-L-seryl-L-leucyl-L-arginyl-L-arginyl-L-seryl-L-seryl-L-cysteinyl-L-phenylalanylglycylglycyl-L-arginyl-L-methionyl-L-aspartyl-L-arginyl-L-isoleucylglycyl-L-alanyl-L-glutaminyl-L-serylglycyl-L-leucylglycyl-L-cysteinyl-L-asparaginyl-L-seryl-L-phenylalanyl-L-arginyl-L-tyrosine cyclic (11-27)-disulfide
    • DTXSID50151238
    • Urodilatin (human)
    • CDD 95-126
    • Inchi： 1S/C145H234N52O44S3/c1-11-72(6)112-137(238)171-60-106(208)172-73(7)113(214)177-86(40-41-103(146)205)122(223)190-95(63-198)116(217)170-61-108(210)175-88(51-70(2)3)114(215)169-62-109(211)176-100(133(234)187-92(56-104(147)206)127(228)193-97(65-200)130(231)186-91(54-77-27-16-13-17-28-77)126(227)180-82(31-20-45-163-142(153)154)119(220)189-94(139(240)241)55-78-36-38-79(204)39-37-78)68-243-244-69-101(134(235)185-90(53-76-25-14-12-15-26-76)115(216)168-58-105(207)167-59-107(209)174-80(29-18-43-161-140(149)150)117(218)182-87(42-50-242-10)123(224)188-93(57-110(212)213)128(229)181-85(124(225)196-112)34-23-48-166-145(159)160)195-132(233)99(67-202)194-131(232)98(66-201)192-120(221)83(32-21-46-164-143(155)156)178-118(219)81(30-19-44-162-141(151)152)179-125(226)89(52-71(4)5)184-129(230)96(64-199)191-121(222)84(33-22-47-165-144(157)158)183-135(236)102-35-24-49-197(102)138(239)74(8)173-136(237)111(148)75(9)203/h12-17,25-28,36-39,70-75,80-102,111-112,198-204H,11,18-24,29-35,40-69,148H2,1-10H3,(H2,146,205)(H2,147,206)(H,167,207)(H,168,216)(H,169,215)(H,170,217)(H,171,238)(H,172,208)(H,173,237)(H,174,209)(H,175,210)(H,176,211)(H,177,214)(H,178,219)(H,179,226)(H,180,227)(H,181,229)(H,182,218)(H,183,236)(H,184,230)(H,185,235)(H,186,231)(H,187,234)(H,188,224)(H,189,220)(H,190,223)(H,191,222)(H,192,221)(H,193,228)(H,194,232)(H,195,233)(H,196,225)(H,212,213)(H,240,241)(H4,149,150,161)(H4,151,152,162)(H4,153,154,163)(H4,155,156,164)(H4,157,158,165)(H4,159,160,166)/t72-,73-,74-,75+,80-,81-,82-,83-,84-,85-,86-,87-,88-,89-,90-,91-,92-,93-,94-,95-,96-,97-,98-,99-,100-,101-,102-,111-,112-/m0/s1
    • InChI Key： IUCCYQIEZNQWRS-DWWHXVEHSA-N
    • SMILES： S1C[C@@H](C(N[C@H](C(NCC(NCC(N[C@@H](CCCNC(=N)N)C(N[C@@H](CCSC)C(N[C@@H](CC(=O)O)C(N[C@H](C(N[C@H](C(NCC(N[C@@H](C)C(N[C@H](C(N[C@H](C(NCC(N[C@H](C(NCC(N[C@H](C(N[C@@H](CC(N)=O)C(N[C@@H](CO)C(N[C@@H](CC2C=CC=CC=2)C(N[C@H](C(N[C@H](C(=O)O)CC2C=CC(=CC=2)O)=O)CCCNC(=N)N)=O)=O)=O)=O)CS1)=O)=O)CC(C)C)=O)=O)CO)=O)CCC(N)=O)=O)=O)=O)[C@@H](C)CC)=O)CCCNC(=N)N)=O)=O)=O)=O)=O)=O)CC1C=CC=CC=1)=O)NC([C@H](CO)NC([C@H](CO)NC([C@H](CCCNC(=N)N)NC([C@H](CCCNC(=N)N)NC([C@H](CC(C)C)NC([C@H](CO)NC([C@H](CCCNC(=N)N)NC([C@@H]1CCCN1C([C@H](C)NC([C@H]([C@@H](C)O)N)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O

Computed Properties

  • Exact Mass: 3503.68000
  • Monoisotopic Mass: 3503.6833625g/mol
  • Isotope Atom Count: 0
  • Hydrogen Bond Donor Count: 60
  • Hydrogen Bond Acceptor Count: 54
  • Heavy Atom Count: 244
  • Rotatable Bond Count: 88
  • Complexity: 8140
  • Covalently-Bonded Unit Count: 1
  • Defined Atom Stereocenter Count: 29
  • Undefined Atom Stereocenter Count : 0
  • Defined Bond Stereocenter Count: 0
  • Undefined Bond Stereocenter Count: 0
  • XLogP3: -17.1
  • Topological Polar Surface Area: 1670?2

Experimental Properties

  • PSA: 1669.02000
  • LogP: -2.69450

Urodilatin Security Information

  • WGK Germany：3

Urodilatin Pricemore >>

Related Categories No. Product Name Cas No. Purity Specification Price update time Inquiry
SHANG HAI JI ZHI SHENG HUA Technology Co., Ltd.
SA02150-0.5mg
Urodilatin
 115966-23-9
0.5mg
 ￥13618.0 2021-09-04
WU HAN AN JIE KAI Biomedical Technology Co., Ltd.
ajci74502-1mg
Urodilatin
 115966-23-9 98%
1mg
 ￥9408.00 2022-04-26
WU HAN AN JIE KAI Biomedical Technology Co., Ltd.
ajci74502-500ug
Urodilatin
 115966-23-9 98%
500ug
 ￥5428.00 2022-04-26
TRC
U846900-500μg
Urodilatin
 115966-23-9
500μg
 415.00 2021-07-15
TRC
U846900-1mg
Urodilatin
 115966-23-9
1mg
 $930.00 2023-05-17
TRC
U846900-2.5mg
Urodilatin
 115966-23-9
2.5mg
 $1849.00 2023-05-17
TRC
U846900-500μg
Urodilatin
 115966-23-9
500μg
 $ 430.00 2022-06-02
LKT Labs
U6857-1mg
Urodilatin CCC
 115966-23-9 ≥98%
1mg
 $700.90 2024-05-20
A2B Chem LLC
AA22143-1mg
Urodilatin
 115966-23-9 ≥95%
1mg
 $785.00 2024-04-20
1PlusChem
1P000HPB-1mg
Urodilatin
 115966-23-9 ≥95%
1mg
 $742.00 2025-02-18

Urodilatin Related Literature

Related Categories

Additional information on Urodilatin

Urodilatin (CAS No. 115966-23-9): A Comprehensive Overview of Its Properties and Therapeutic Potential

Urodilatin (CAS No. 115966-23-9) is a natriuretic peptide that has garnered significant attention in the medical and pharmaceutical communities. This 32-amino acid peptide is structurally similar to atrial natriuretic peptide (ANP) but is primarily produced in the kidneys. Its unique properties make it a promising candidate for treating various cardiovascular and renal conditions. In this article, we delve into the chemical properties, mechanisms of action, and therapeutic applications of Urodilatin, while also exploring its market potential and recent advancements.

The chemical structure of Urodilatin includes a ring formed by a disulfide bond between two cysteine residues, which is critical for its biological activity. Unlike ANP, which is degraded quickly in the bloodstream, Urodilatin exhibits greater stability, making it more effective for therapeutic use. Researchers have identified its role in regulating blood pressure, sodium excretion, and fluid balance, which are key factors in managing conditions like heart failure and acute kidney injury.

One of the most discussed topics in recent years is the potential of Urodilatin in treating acute decompensated heart failure (ADHF). Patients with ADHF often experience severe fluid overload, and conventional diuretics may not always be effective. Urodilatin offers a novel approach by promoting natriuresis and diuresis without causing significant electrolyte imbalances. Clinical trials have shown promising results, with patients experiencing improved renal function and reduced hospitalization rates.

Another area of interest is the use of Urodilatin in critical care medicine. Its ability to improve renal perfusion and reduce inflammatory responses makes it a valuable tool for managing sepsis-associated acute kidney injury (SA-AKI). With the rising incidence of sepsis worldwide, the demand for effective treatments is higher than ever. Urodilatin could potentially fill this gap, offering a safer and more targeted therapy compared to traditional approaches.

From a market perspective, the global interest in Urodilatin is growing. Pharmaceutical companies are investing heavily in research and development to bring Urodilatin-based therapies to market. The peptide's unique mechanism of action and favorable safety profile make it an attractive option for drug development. Analysts predict that the Urodilatin market will experience significant growth in the coming years, driven by the increasing prevalence of cardiovascular and renal diseases.

In addition to its therapeutic potential, Urodilatin research is also contributing to our understanding of natriuretic peptide signaling pathways. Scientists are exploring how these pathways can be modulated to develop new treatments for a wide range of conditions. This research is not only advancing medical science but also opening doors for innovative biomarker development and personalized medicine approaches.

For those interested in the synthesis of Urodilatin, it’s worth noting that the peptide can be produced using recombinant DNA technology or solid-phase peptide synthesis (SPPS). These methods ensure high purity and yield, which are essential for clinical applications. Quality control measures, such as HPLC analysis and mass spectrometry, are routinely employed to verify the integrity of the peptide.

In conclusion, Urodilatin (CAS No. 115966-23-9) represents a groundbreaking advancement in the field of peptide therapeutics. Its unique properties and wide-ranging applications make it a subject of intense research and commercial interest. As more clinical data becomes available, Urodilatin is poised to become a cornerstone in the treatment of cardiovascular and renal disorders. Stay tuned for further updates on this exciting molecule as it continues to make waves in the medical community.

115966-23-9 (Urodilatin) Related Products

Recommended suppliers
Xiamen PinR Bio-tech Co., Ltd.
Gold Member
Audited Supplier Audited Supplier
CN Supplier
Bulk
Xiamen PinR Bio-tech Co., Ltd.
Shenzhen Yaoyuan R&D Center Co.,Ltd
Gold Member
Audited Supplier Audited Supplier
CN Supplier
Bulk
Shenzhen Yaoyuan R&D Center Co.,Ltd
Hebei Liye chemical Co.,Ltd
Gold Member
Audited Supplier Audited Supplier
CN Supplier
Bulk
Hebei Liye chemical Co.,Ltd
Jinan Hanyu Chemical Co.,Ltd.
Gold Member
Audited Supplier Audited Supplier
CN Supplier
Bulk
Jinan Hanyu Chemical Co.,Ltd.
Nanjing jingzhu bio-technology Co., Ltd.
Gold Member
Audited Supplier Audited Supplier
CN Supplier
Bulk
Nanjing jingzhu bio-technology Co., Ltd.